World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
41857
World Ranking
13877
National Ranking
7045

Saad Z. Usmani publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Saad Z. Usmani sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 908 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Saad Z. Usmani D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Saad Z. Usmani sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Saad Z. Usmani is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on hematology and oncology, with a strong emphasis on multiple myeloma and related therapeutic approaches.

The scientist's work spans several fields, including Medicine and Biochemistry, Genetics, and Molecular Biology. Subfields of study include Hematology, Oncology, Molecular Biology, Genetics, and Immunology. Their research topics cover multiple myeloma research and treatments, protein degradation and inhibitors, CAR-T cell therapy research, peptidase inhibition and analysis, chronic lymphocytic leukemia research, monoclonal and polyclonal antibodies research, and cancer treatment and pharmacology.

Some of the recent significant papers authored or co-authored by Saad Z. Usmani include:

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study, 2021, The Lancet
  • Teclistamab in Relapsed or Refractory Multiple Myeloma, 2022, New England Journal of Medicine
  • Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up, 2022, Journal of Clinical Oncology
  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches, 2020, Leukemia
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study, 2020, The Lancet

Frequent co-authors collaborating with Saad Z. Usmani include:

  • Alexander M. Lesokhin
  • Kylee Maclachlan
  • Sham Mailankody
  • Urvi A. Shah
  • Neha Korde

The most common venues for publishing their research are Blood, Clinical Lymphoma Myeloma & Leukemia, Journal of Clinical Oncology, Blood Cancer Journal, and Transplantation and Cellular Therapy.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesus G Berdeja;Deepu Madduri;Saad Z Usmani;Andrzej Jakubowiak

  • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

    Sagar Lonial;Hans C Lee;Ashraf Z Badros;Suzanne Trudel

  • IMWG consensus on risk stratification in multiple myeloma

    W J Chng;A Dispenzieri;C-S Chim;R Fonseca

  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

    Ujjawal H. Gandhi;Robert F. Cornell;Arjun Lakshman;Zhubin J. Gahvari

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michele Cavo;Evangelos Terpos;Cristina Nanni;Philippe Moreau

  • Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

    Saad Z. Usmani;Brendan M. Weiss;Torben Plesner;Nizar J. Bahlis

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

    Saad Z. Usmani;Christoph Heuck;Alan Mitchell;Jackie Szymonifka

  • Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

    Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

    Meletios Dimopoulos;Hang Quach;Maria-Victoria Mateos;Ola Landgren

  • International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Jens Hillengass;Saad Usmani;S Vincent Rajkumar;Brian G M Durie

  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

    Nina Shah;Ajai Chari;Emma Scott;Khalid Mezzi

  • Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

    Antonio Palumbo;Sara Bringhen;Shaji K Kumar;Giulia Lupparelli

  • CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.

    Niels W.C.J. van de Donk;Saad Z. Usmani

Frequent Co-Authors

Bart Barlogie
Bart Barlogie Mount Sinai Hospital
Shaji Kumar
Shaji Kumar Mayo Clinic
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Frits van Rhee
Frits van Rhee University of Arkansas for Medical Sciences
Parameswaran Hari
Parameswaran Hari Medical College of Wisconsin
Sagar Lonial
Sagar Lonial Emory University
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Paul G. Richardson
Paul G. Richardson Harvard University
Michele Cavo
Michele Cavo University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the healthcare field goes beyond traditional medical school paths. Many students consider flexible online programs that offer faster or more affordable routes to rewarding medical careers. For registered nurses seeking to advance their education, finding what is the cheapest rn to bsn program online is an important step, helping to balance cost and quality.

Those with a bachelor’s degree in a non-nursing field may look into direct entry msn programs for non nurses online. These programs offer a fast track into advanced nursing roles by leveraging your previous degree.

If you’re in search of less competitive entry requirements, research is available on the easiest nursing schools to get into, making it possible for more students to begin their healthcare education journey without high barriers.

Alternatively, a career in healthcare administration is also accessible through online education. For those interested in supportive roles, exploring the best online medical billing and coding schools can open doors to vital positions with strong job prospects.

Best Scientists Citing Saad Z. Usmani

Trending Scientists

Recently Published Articles